Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis

British Journal of Clinical Pharmacology

Volumn 78, Issue 1, 2014, Pages 118-128

  Ternant, David ^a,b,c   Ducourau, Emilie ^a,b,c   Perdriger, Aleth ^d   Corondan, Anca ^e   Le Goff, Benoît ^f   Devauchelle Pensec, Valérie ^g   Solau Gervais, Elisabeth ^h   Watier, Hervé ^a,b,c   Goupille, Philippe ^a,b,c,i   Paintaud, Gilles ^a,b,c   Mulleman, Denis ^a,b,c,i  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITÉ DE NICE SOPHIA ANTIPOLIS   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g Universite de Brest   (France)

^h POITIERS UNIVERSITY HOSPITAL   (France)

ⁱ INSERM   (France)

Author keywords

inflammation; infliximab; monoclonal antibodies; pharmacokinetics; rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; METHOTREXATE; PREDNISONE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CORRELATIONAL STUDY; DISEASE ACTIVITY; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG INFUSION; DRUG STABILITY; FEMALE; HUMAN; INFLAMMATION; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFLAMMATION; INFLIXIMAB; MALE; METHOTREXATE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDNISONE;

EID: 84902971236     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12313     Document Type: Article

References (24)

1. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC,. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-1459.
2. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T,. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006; 54: 3782-3789.
3. Mulleman D, Chu Miow Lin D, Ducourau E, Emond P, Ternant D, Magdelaine-Beuzelin C, Valat JP, Paintaud G, Goupille P,. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit 2010; 32: 232-236.
4. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L,. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 704-707.
5. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H,. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009; 65: 1211-1228.
6. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G,. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30: 523-529.
7. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, Davis HM, Zhou H,. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008; 48: 681-695.
8. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M,. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563.
9. Fautrel B, Pham T, Mouterde G, Le Loet X, Goupille P, Guillemin F, Ravaud P, Cantagrel A, Dougados M, Puechal X, Sibilia J, Soubrier M, Mariette X, Combe B,. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007; 74: 627-637.
10. Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G,. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006; 28: 169-174.
11. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
12. Comets E, Brendel K, Mentre F,. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-166.
13. Ternant D, Mulleman D, Lauféron F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G,. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 2012; 73: 55-65.
14. Gibiansky L, Gibiansky E,. Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics. Expert Opin Drug Metab Toxicol 2009; 5: 803-812.
15. Mager DE, Jusko WJ,. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-532.
16. Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, Charles PJ, Taylor PC, Feldmann M,. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 1995; 144: 195-223.
17. Elliott MJ, Maini RN,. Anti-cytokine therapy in rheumatoid arthritis. Baillieres Clin Rheumatol 1995; 9: 633-652.
18. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, Molina R, Ballesta A, Munoz-Gomez J,. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994; 33: 927-931.
19. Mulleman D, Lauféron F, Wendling D, Ternant D, Ducourau E, Paintaud G, Goupille P,. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther 2011; 13: R82.
20. Ducourau E, Mulleman D, Paintaud G, Chu Miow Lin D, Lauféron F, Ternant D, Watier H, Goupille P,. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011; 13: R105.
21. Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL,. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007; 64: 278-291.
22. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, Ruiz Del Agua A, Martinez A, Aarden L, Martin-Mola E, Balsa A,. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1445-1452.
23. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B,. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-715.
24. Mulleman D, Ducourau E, Paintaud G, Ternant D, Watier H, Goupille P,. Should anti-TNF-alpha drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis? Joint Bone Spine 2012; 79: 109-112.